Comparative Analysis Of Treatment Outcomes In Patient With Diabetes Mellitus

Abstract

Diabetes mellitus (DM) is a long-term disease that shows hyperglycemia resulting from either reduced insulin sensitivity or inadequate endogenous insulin or both. Since its current global rise, especially in Type 2 diabetes mellitus, this condition poses a significant challenge to effective disease management in today’s populous world. There are several treatment options for diabetes – patients can change their diets and see a nutritionist, and the mild case may be treated with prescription pills, and if not, they might have to go for injections, including insulin and GLP-1 receptor agonists. However, the outcomes of treatment is thoroughly different in different groups of patients and depends on several factors including patients’ compliance, the level of patients’ socio-economic status, the presence of concurrent diseases and the choice of proper individualized treatment. The intent is to compare the effectiveness of various treatment regimens in terms of glycaemic goals and microvascular and macrovascular complications like cardiovascular disease, nephropathy, neuropathy and retinopathy. Also, the work aims at finding out the causes of variations in these patient outcomes, information that can promote understanding of the solutions to make those treatment more effective in diabetes control. As such, this research offers useful knowledge of the efficacy of several treatment plans, and the application of customized treatment in diabetes. The results of the proposed research are expected to provide more insights to the healthcare practitioners concerning ways to tailor the course of treatment regimens according to the need, capacity and preference of the patient as well as increase compliance and thus enhance the general wellbeing of a patient. Consequently, this work strengthens the development of the latest approaches to diabetes treatment, while lowering the global burden of this disease and improving the quality of patient lives.